2. Academic Validation
  3. Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury

Identification and Mitigation of Reactive Metabolites of 2-Aminoimidazole-Containing Microsomal Prostaglandin E Synthase-1 Inhibitors Terminated Due to Clinical Drug-Induced Liver Injury

  • J Med Chem. 2018 Mar 8;61(5):2041-2051. doi: 10.1021/acs.jmedchem.7b01806.
Bryan H Norman,  Matthew J Fisher,  Matthew A Schiffler,  Steven L Kuklish,  Norman E Hughes,  Boris A Czeskis,  Kenneth C Cassidy,  Trent L Abraham,  Jeffrey J Alberts,  Debra Luffer-Atlas
PMID: 29425457 DOI: 10.1021/acs.jmedchem.7b01806
Abstract

Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans. We studied imidazole ring substitutions to successfully mitigate reactive metabolite (RM) formation. These studies support the conclusion that RM formation may play a role in the observations of DILI and the consideration of 2-aminoimidazoles as structure alerts, due to the high likelihood of bioactivation to generate RMs.

Figures
Products